Standard of Care: Enzyme Replacement Therapy (ERT)

For many years, the only way to manage alpha-mannosidosis was by treating individual symptoms as they appeared. Today, enzyme replacement therapy (ERT) offers a way to address the underlying cause of the disease in the body by replacing the missing enzyme ^[1]. The primary medication for this is velmanase alfa ^[1].

Note: Regulatory approvals, age eligibility, and reimbursement for velmanase alfa vary by country. In jurisdictions where it is approved, it is generally indicated for treating non-neurological manifestations in mild-to-moderate disease.

How Velmanase Alfa Works

Velmanase alfa is a lab-made version of the human alpha-mannosidase enzyme ^[2]. When it is infused into the bloodstream, it travels to the cells and enters the lysosomes (the recycling centers) to help break down the mannose-rich sugars that have built up ^[2][1].

It is important to understand a key limitation: ERT is not a cure and is designed to treat “somatic” (body-related) symptoms ^[3]. Because the medication does not cross the blood-brain barrier—a protective shield that prevents many substances from entering the brain—it is not effective for the neurological or cognitive aspects of the condition ^[2][4].

Dosing and Administration

• Dose: The standard dose is typically 1 mg per kilogram of body weight ^[1].
• Frequency: It is given as an intravenous (IV) infusion once every week ^[5].
• Duration: The infusion rate and duration depend on the product label and the center’s specific protocol, often taking a few hours. This is in addition to the observation time required before and after the infusion ^[4].

Goals of Treatment

The goals of ERT are to slow the progression of the somatic disease and potentially improve physical function ^[5].

1. Biochemical Response: One of the clearest signs the medicine is working is a significant drop in serum oligosaccharides (sugars in the blood) ^[1].
2. Physical Mobility: Studies show that patients on ERT may experience improved or stabilized results on functional tests like the 3-minute stair-climb test or the 6-minute walk test ^[6][5].
3. Infection Burden: Clinical trials have monitored immune parameters (like IgG levels) and tracked infection rates. While some patients experience a reduction in recurrent infections during treatment, this does not mean total immune function is normalized, and results vary from person to person ^[7].

Managing Risks and Side Effects

Like any infusion therapy, velmanase alfa carries risks, and safety monitoring is critical ^[5].

• Infusion-Related Reactions (IRRs): Reactions can happen during or shortly after the infusion ^[4]. Symptoms can include fever, chills, rash, or breathing difficulties ^[4]. Severe hypersensitivity or anaphylaxis is possible. If severe breathing difficulty, swelling, or rash occurs, emergency medical action is required. Your doctor may prescribe individualized “premedications” (like antihistamines) to prevent reactions, and your center will have an emergency response plan ^[4].
• Anti-Drug Antibodies (ADAs): Because the medication is a foreign protein, the immune system may create antibodies against it ^[8]. Your doctor will monitor ADA levels; while many patients with antibodies still benefit from the drug, high levels can sometimes be associated with infusion reactions or changes in drug effectiveness ^[8][4].

Long-Term Monitoring

Starting ERT is a long-term commitment. Your care team will track treatment effectiveness and safety using blood tests (for oligosaccharides and IgG), functional mobility tests, and general health checks covering hearing, lung function, and quality of life ^[9][1].